Presentations we supply
- Injection 250 mg/5 ml
Tell us whether you need the originator brand or a generic, the strength, pack and quantity, and the destination country.
Send Enquiry for FulvestrantReference information
Summarised from the product information for Faslodex. Always follow the product information approved in your own country.
- Active substance
- Fulvestrant
- Pharmacotherapeutic group
- Endocrine therapy, anti-oestrogens (ATC code L02BA03)
- Authorised uses
- Oestrogen receptor-positive, locally advanced or metastatic breast cancer in postmenopausal women, as a single agent
- As a single agent: when not previously treated with endocrine therapy, or after relapse or progression on anti-oestrogen therapy
- With palbociclib: hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after prior endocrine therapy
- In pre- or perimenopausal women, the combination with palbociclib is given with an LHRH agonist
- Storage (unopened)
- Store and transport in a refrigerator (2 °C to 8 °C); limited temperature excursions are allowed as set out in the product information. Store the pre-filled syringe in the original package in order to protect from light.
- Shelf life (unopened)
- 4 years
- Container and pack
- Type I glass pre-filled syringe (5 ml) with safety needle; packs of 1 or 2 syringes
Supply from Bio Bridge Pharma
- The registration route and import licence are confirmed for your destination before we make an offer.
- Documents agreed before you order, such as the batch certificate of analysis and a CoPP where your regulator needs one.
- Cold-chain shipment for this refrigerated product.
- Named patient supply where the destination country's rules allow it.
Sources
- Product information for Faslodex: www.ema.europa.eu